Oncology

  1. Perjeta (pertuzumab)
    Perjeta (pertuzumab)
    by Roche Registration Limited
    for Breast Cancer
    €2,615.03
  2. Portrazza (necitumumab)
    Portrazza (necitumumab)
    by Eli Lilly Nederland B.V.
    for Lung Cancer
    €572.25
  3. Rubraca (rucaparib)
    Rubraca (rucaparib)
    by Clovis Oncology, Inc.
    for Gynaecological Cancer
    €10,982.50
  4. Rydapt (midostaurin)
    Rydapt (midostaurin)
    by Novartis Europharm Limited
    for Leukemia
    €15,592.50
  5. Tagrisso (osimertinib)
    Tagrisso (osimertinib)
    by AstraZeneca AB
    for Lung Cancer
    €7,103.20
  6. Tecentriq (atezolizumab)
    Tecentriq (atezolizumab)
    by Roche Registration Limited
    for Urothelial Carcinoma, Lung Cancer
    €5,510.93
  7. Zejula (niraparib)
    Zejula (niraparib)
    by Tesaro UK Limited
    for Gynaecological Cancer
    €7,323.75
  8. Lartruvo (olaratumab)
    Lartruvo (olaratumab)
    by Eli Lilly Nederland B.V.
    for Soft Tissue Sarcoma
    €660.00
View as Grid List

Items 28-35 of 35

Page
per page
Set Descending Direction